Status:
SUSPENDED
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Lead Sponsor:
Roger Williams Medical Center
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to collect data on the safety and effectiveness of 2nd generation designer T cells in patients with breast cancer. Designer T cells are prepared by collecting white blood ...
Detailed Description
T cells can penetrate virtually every biologic space and have the power to dispose of normal or malignant cells as seen in viral and autoimmune diseases and in the rare spontaneous remissions of cance...
Eligibility Criteria
Inclusion
- Must have cancer of the breast
- Must have metastatic or unresectable locally advanced disease
- Tumor must express CEA by tumor staining or by elevated serum CEA (\>10 ng/ml)
- Must have measurable disease radiologically or by physical exam
- Must have failed potentially curative standard therapy
- Must be 18 years of age or older
- Good performance status (PS 0-1)
Exclusion
- Requiring systemic steroids
- Serious medical conditions
- Concurrent malignancies
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00673829
Start Date
May 1 2008
End Date
December 1 2018
Last Update
June 17 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tufts University Medical Center
Boston, Massachusetts, United States, 02115
2
Roger Williams Medical Center
Providence, Rhode Island, United States, 02908